Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessing cognitive improvement in people with Down syndrome: important considerations for drug-efficacy trials.

Handbook of experimental pharmacology - 1 Jan 2015

Fernandez Fabian, Reeves Roger H

Abstract excerpt

Experimental research over just the past decade has raised the possibility that learning deficits connected to Down syndrome (DS) might be effectively managed by medication. In the current chapter, we touch on some of the work that paved the way for these advances and discuss the challenges associated with translating them. In particular, we highlight sources of phenotypic variability in the DS population that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Behavior, Animal
Share to Brain
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cognition

Share to Down Syndrome

Share to Learning

Share to Recovery of Function

Share to Research Design

Source

Identifiers

PMID: 25977089
DOI: 10.1007/978-3-319-16522-6_12

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessing cognitive improvement in people with Down syndrome: important considerations for drug-efficacy trials.PMID 25977089Read ↗

Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerationsSemantic proximity Read ↗

Human and mouse model cognitive phenotypes in Down syndrome: implications for assessment.Semantic proximity Read ↗

The LonDownS adult cognitive assessment to study cognitive abilities and decline in Down syndromeSemantic proximity Read ↗

Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down Syndrome.Semantic proximity Read ↗

Prenatal and Postnatal Pharmacotherapy in Down Syndrome: The Search to Prevent or Ameliorate Neurodevelopmental and Neurodegenerative DisordersSemantic proximity Read ↗

Cognitive Changes associated with Alzheimer’s disease in Down syndromeSemantic proximity Read ↗

Behavioral phenotype of individuals with Down syndrome.Semantic proximity Read ↗

Cognitive and pharmacological insights from the Ts65Dn mouse model of Down syndromeSemantic proximity Read ↗

Age-related changes of adaptive and neuropsychological features in persons with Down Syndrome.Semantic proximity Read ↗

Down syndrome: Cognitive and behavioral functioning across the lifespan.Semantic proximity Read ↗

Alzheimer’s Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention TrialsSemantic proximity Read ↗

Molecular basis of pharmacotherapies for cognition in Down syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.